Science Explorer Back to mapMap
Discussion
Researcher · Hospital Costa del Sol · Spain

Antonio Rueda

Antonio Rueda publishes mostly in Oncology, Pathology and Forensic Medicine and Molecular Biology, on topics such as Lymphoma Diagnosis and Treatment, Viral-associated cancers and disorders and Head and Neck Cancer Studies.

OpenAlex
World rank
#2,115,990
of 7,710,434 ranked researchers
Rank in Spain
#45,592
of 204,306
Works
122
Citations
3.1k
Citations per work
25.7
h-index
26
i10-index 61Top 15% in Oncology
Antonio Rueda

What does Antonio Rueda research?

Antonio Rueda's work is mostly in Medicine (42%), Biochemistry, Genetics and Molecular Biology (26%).

Health Sciences: 51 works · 41.5% of their workMedicine: 51 works · 41.5% of their workOncology: 25 works · 20.6% of their workPathology and Forensic Medicine: 18 works · 15.1% of their workPulmonary and Respiratory Medicine: 7 works · 5.8% of their workEverything else: 39 works · 32.2% of their workLife Sciences: 32 works · 26.3% of their workBiochemistry, Genetics and Molecular Biology: 32 works · 26.3% of their workMolecular Biology: 17 works · 14.1% of their workCancer Research: 9 works · 7.4% of their workGenetics: 6 works · 4.8% of their workTHEIR WORKAntonio Rueda122works
Life Sciences26%Health Sciences42%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine5141.5%
  2. Everything else3932.2%
    1. Biochemistry, Genetics and Molecular Biology3226.3%
  1. 1Oncology21% of their works
  2. 2Pathology and Forensic Medicine15% of their works
  3. 3Molecular Biology14% of their works
  4. 4Cancer Research7% of their works
  5. 5Pulmonary and Respiratory Medicine6% of their works
  6. 6Genetics5% of their works

Research topics

Which keywords describe Antonio Rueda's research?

The keywords of their largest research topics: Rituximab, Classification, Lymphoma, Chemotherapy, Radiotherapy, Cancer Incidence, Prognostic Factors and Epstein-Barr Virus.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 21 words, with their numbers
  1. Rituximab502 topics
  2. Classification391 topic
  3. Lymphoma391 topic
  4. Chemotherapy212 topics
  5. Radiotherapy212 topics
  6. Cancer Incidence192 topics
  7. Prognostic Factors182 topics
  8. Epstein-Barr Virus121 topic
  9. Human Papillomavirus121 topic
  10. Kaposi's Sarcoma121 topic
  11. Oropharyngeal Cancer121 topic
  12. Chronic Lymphocytic Leukemia111 topic
  13. Genomic Aberrations111 topic
  14. Primary CNS Lymphoma91 topic
  15. Prognostic Scoring System91 topic
  16. RNA methylation91 topic
  17. m6A-seq91 topic
  18. Cutaneous Lymphomas71 topic
  19. Global Surveillance71 topic
  20. Mortality Rates71 topic
  21. Mycosis Fungoides71 topic

Where does Antonio Rueda work?

Antonio Rueda's main affiliation in the publication record is Hospital Costa del Sol, Spain.

How many publications and citations does Antonio Rueda have?

OpenAlex counts 122 works and 3,139 citations for Antonio Rueda, an h-index of 26, ranking #2,115,990 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Antonio Rueda. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.